Anti-blastocystis activity of hop extracts in vitro
DOI:
https://doi.org/10.26641/2307-0404.2024.1.300778Keywords:
anti-Blastocystis activity, hop extracts, metronidazoleAbstract
Blastocystis sp. are the most common, unicellular, anaerobic parasites of the intestinal tract of many animal and human species that can cause various digestive diseases. Metronidazole has long been used as a first-line treatment for blastocystosis, but recent clinical and in vitro studies have demonstrated its low efficacy against Blastocystis sp. The aim of this study was to determine the in vitro sensitivity of Blastocystis sp. clinical isolates to carbonic acid hop extracts and alcohol hop extracts in comparison with metronidazole. Five cultures of Blastocystis sp. were isolated from faecal samples from patients with irritable bowel syndrome with predominant diarrhoea (IBS-D, Rome IV). The parasites were identified by microscopy of faecal smears permanently stained with trichrome, Wheatley’s modification and Heidenhain’s iron-haematoxylin. Blastocystis sp. was cultivated at 37°C under anaerobic conditions on RPMI-1640 with antibiotics and horse serum, taking into account their growth characteristics. To detect the antiblastocystic activity hop extracts and metronidazole were tested in the range from 1000 μg/ml to 1 μg/ml.The presence and number of viable Blastocystis sp. cells were determined after 24, 48, 72 and 96 hours. Blastocystis sp. cells were counted in a hemocytometer using the trypan blue dye exclusion test. All experiments were performed in triplicate. According to the results of in vitro sensitivity of 5 clinical isolates of Blastocystis sp. to the action of carbonic acid hop extract, alcohoicl hop extract and metronidazole, a direct positive pattern in the dose-response and contact time-response effects was established. Alcoholic hop extract showed the highest level of antiblastocystic activity with indicators (for 72-hour parasite cultures) of the minimum inhibitory concentration (which inhibits the parasite cultures growth by 50%) (2.8±0,8) μg/ml and the minimum lethal concentration (which destroys parasite cells by 100%) – 8 μg/ml, being 2.4 and 4.5 times lower than the minimum inhibitory concentration and 8 and 62.5 times lower, than the minimum lethal concentration for hop extract and metronidazole, respectively (p<0.05). It has been shown that alcoholic hop extract (≥16 μg/ml) causes gradual morphological changes in Blastocystis sp. cells, leading to their complete destruction.In contrast to metronidazole, subinhibitory concentrations of hop extract (<2 μg/ml) do not stimulate the proliferation of Blastocystis sp. cells in vitro.
References
Rudzinska M, Sikorska K. Epidemiology of Blastocystis infection: A review of data from Poland in relation to other reports. Pathogens. 2023;12(8):1050. doi: https://doi.org/10.3390/pathogens12081050
Stensvold CR, Tan KSW, Clark CG. Blastocystis. Trends Parasitol. 2020 Mar;36(3):315-6. doi: https://doi.org/10.1016/j.pt.2019.12.008
Ajjampur SSR, Tan KSW. Pathogenic mecha-nisms in Blastocystis spp. – Interpreting results from in vitro and in vivo studies. Parasitol Int. 2016;65(6):772-9. doi: https://doi.org/10.1016/j.parint.2016.05.007
Deng L, Wojciech L, Gascoigne NRJ, Peng G, Tan KSW. New insights into the interactions between Blastocystis, the gut microbiota, and host immunity. PLoS Pathog. 2021 Feb 25;17(2):e1009253. doi: https://doi.org/10.1371/journal.ppat.1009253
ICD-11 for Mortality and Morbidity Statistics. Version: 05/2021 [Internet]. 2021 [cited 2023 Oct 01]. Available from: https://icd.who.int/browse11/l-m/en#/
http://id.who.int/icd/entity/1184241320
Shirvani G, Fasihi-Harandi M, Raiesi O, Bazargan N, et al. Prevalence and molecular subtyping of Blastocystis from patients with irritable bowel syndrome, inflammatory bowel disease and chronic urticaria in Iran. Acta Parasitol. 2020;65(1):90-6. doi: https://doi.org/10.2478/s11686-019-00131-y
Peña S, Carrasco G, Rojas P, Castillo D, et al. Deter¬mination of subtypes of Blastocystis sp. in Chilean patients with and without inflammatory bowel syndrome, a preli¬minary report. Parasite Epidemiol Control. 2020;8:e00125. doi: https://doi.org/10.1016/j.parepi.2019.e00125
Vielma JR. Blastocystosis: epidemiological, clinical, pathogenic, diagnostic, and therapeutic aspects. Invest Сlin. 2019 Mar;60(1):53-78. doi: https://doi.org/10.22209/IC.v60n1a06
Butters C, Yeoh DK, Curtis N. Parasites in Human Stool: to ignore or not to ignore ? Pediatr Infect Dis J. 2019 June;38(6S):S47-S51. doi: https://doi.org/10.1097/INF.0000000000002323
Rojas-Velázquez L, Moran P, Serrano-Vázquez A, et al. The regulatory function of Blastocystis spp. on the immune inflammatory response in the gut micro-biome. Front Cell Infect Microbiol. 2022 Aug 31;12:967724. doi: https://doi.org/10.3389/fcimb.2022.967724
Badparva E, Kheirandish F. Blastocystis hominis: A Pathogenic Parasite. Arch Clin Infect Dis. 2020;15(4):e97388. doi: https://doi.org/10.5812/archcid.97388
Batista L, Pérez JJ, Rosinach M, Gonzalo V, et al. Low efficacy of metronidazole in the eradication of Blastocystis hominis in symptomatic patients: Case series and systematic literature review. Gastroenterol Hepatol. 2017 Jun-Jul;40(6):381-7. doi: https://doi.org/10.1016/j.gastrohep.2016.11.003
Rajamanikam A, Kumar S, Samudi C, Kudva M. Exacerbated symptoms in Blastocystis sp.-infected pa-tients treated with metronidazole: two case studies. Parasitol Res. 2018 Aug;117(8):2585-90. doi: https://doi.org/10.1007/s00436-018-5948-x
Rajamanikam A, Hooi HS, Kudva M, et al. Resis¬tance towards metronidazole in Blastocystis sp.: A pathogenic consequence. PLoS One. 2019 Feb;14(2):e0212542. doi: https://doi.org/10.1371/journal.pone.0212542
Cobuccio LG, Laurent M, Gardiol C, Wampfler R, et al. Should we treat Blastocystis sp.? A double-blind placebo-controlled randomized pilot trial. J Travel Med. 2023 Jan;30(1):taac143. doi: https://doi.org/10.1093/jtm/taac143
El-Sayed NM, Masoud NG. Medical Plants as Natural Antiparasitic Agents Against Blasocystis species. Cur Pharmac Design. 2023;18(1):2-15. doi: https://doi.org/10.2174/2772434418666221124123445
Ojuromi OT, Ashafa AO. An overview of some medicinal plants and isolated active compounds with potential antiprotozoal activity. Trop J Pharmac. Res. 2020;19(7):1551-63. doi: https://doi.org/10.4314/tjpr.v19i7.30
Mokhtar AB, Ahmed SA, Eltamany EE, Kara-nis P. Anti-Blastocystis Activity In Vitro of Egyptian Herbal Extracts (Family: Asteraceae) with Emphasis on Artemisia judaica. Int J Environ Res Public Health. 2019 May;16(9):1555. doi: https://doi.org/10.3390/ijerph16091555
Astray G, Gullón P, Gullón B, Munekata PES, Lorenzo JM. Humulus lupulus L. as a Natural Source of Functional Biomolecules. Applied Sciences. 2020;10(15):5074. doi: https://doi.org/10.3390/app10155074
Liu M, Hansen P, Wang G, Qiu L, et al. Pharmacological Profile of Xanthohumol, a Prenylated Flavonoid from Hops (Humulus lupulus). Molecules. 2015 Jan;20(1):754-79. doi: https://doi.org/10.3390/molecules20010754
Jiang CH, Sun TL, Xiang DX, Wei SS, Li WQ. Anticancer Activity and Mechanism of Xanthohumol: A Prenylated Flavonoid From Hops (Humulus lupulus L.). Front Pharmacol. 2018 May;9:5309. doi: https://doi.org/10.3389/fphar.2018.00530
Frölich S, Schubert C, Bienzle U, Jenett-Siems K. In vitro antiplasmodial activity of prenylated chalcone derivatives of hops (Humulus lupulus) and their interaction with haemin. J Antimicrob Chemother. 2005 Jun;55(6):883-7. doi: https://doi.org/10.1093/jac/dki099
Bocquet L, Sahpaz S, Bonneau N, et al. Phenolic Compounds from Humulus lupulus as Natural Antimicrobial Products: New Weapons in the Fight against Methicillin Re¬sistant Staphylococcus aureus, Leishmania mexicana and Trypanosoma brucei Strains. Molecules. 2019 Mar;24(6):1024. doi: https://doi.org/10.3390/molecules24061024
Srinivasan V, Goldberg D, Haas GJ. Contributions to the Antimicrobial Spectrum of Hop Constituents. Econ Bot. 2004;58(sp1):S230-S238. doi: https://doi.org/10.1663/0013-0001(2004)58[s230:cttaso]2.0.co;2
Garcia LS, Campbell JL, Fritsche TR, Hummer B, et al. Procedures for the Recovery and Identification of Parasites from Intestinal Tract; Approved Guideline - Second Edition. CLSI document M28-A2. Clinical and Laboratory Standards Institute. 2005;25(16):111.
Pokhill S, Tymchenko O, Chigirinskaya N, Kostyria I, et al. [Regularities of primary growth of Blastocystis sp. in five types of nutrient media]. Annals of Mechnikov’s Institute. 2021;4:45-53. Ukrainian. doi: https://doi.org/10.5281/zenodo.5761243
Strober W. Trypan Blue Exclusion Test of Cell Viability. Curr Protoc Immunol. 2015 Nov;111:A3.B.1-A3.B.3. doi: https://doi.org/10.1002/0471142735.ima03bs111
Ragavan AD, Govind SK. Modified Fields' stain: ideal to differentiate Dientamoeba fragilis and Blastocystis sp. Parasitol Res. 2015 Mar;114(3):1163-6. doi: https://doi.org/10.1007/s00436-014-4296-8
Sio SWS, Puthia MK, Lee ASY, et al. Protease activity of Blastocystis hominis. Parasitol Res. 2006;99(2):126-30. doi: https://doi.org/10.1007/s00436-006-0131-1
Franklin F, Rajamanikam A, Raju CS, et al. Hig-her amoebic and metronidazole resistant forms of Bla-stocystis sp. seen in schizophrenic patients. Parasites & Vectors. 2022 Sep;15(1):313. doi: https://doi.org/10.1186/s13071-022-05418-0
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Medicni perspektivi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.